Sweden's Orexo granted AstraZeneca the right to carry out further preclinical work and evaluation of compounds in its OX-CLI program targeted for respiratory diseases. AstraZeneca was also given the option to purchase the compounds in the program. The deal entitles Orexo to possible milestone fees and royalties.

Full Story:
PharmaTimes (U.K.)

Related Summaries